Seladelpar (, ; developmental code names MBX-8025, RWJ-800025) is a
PPARĪ“ receptor agonist that is being investigated for drug use by Metabolex.
According to a
press release they are examining its potential use for the treatment of
dyslipidemia,
metabolic syndrome
Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).
Metabolic syndrome ...
,
type 2 diabetes, and
non-alcoholic steatohepatitis (NASH). The compound was licensed from
Janssen Pharmaceutica NV.
See also
*
Elafibranor
Elafibranor (INN, code name GFT505) is an experimental medication that is being studied and developed by Genfit for the treatment of cardiometabolic diseases including diabetes, insulin resistance, dyslipidemia, and non-alcoholic fatty liver dis ...
*
GW501516
*
Peroxisome proliferator-activated receptor
References
External links
Seladelpar - AdisInsight
Carboxylic acids
Experimental drugs
PPAR agonists
Trifluoromethyl compounds
{{Gastrointestinal-drug-stub